The September scorecard for the signals generated from Sonal can be downloaded here. The results are summarized in this table: Scorecard Total Repurchases M&A Guidance Contracts Clinical Trials Correct – Prev Close to Next Close 68% 59% 68% 93% 64% 68% Correct – Prev Close to Next Session Peak 92% 85% 90% 100% 100% 94% […]
Read more...
On October 12, PAR Technology Corporation (PAR) announced that its subsidiary, Rome Research Corporation, received U.S. Air Force subcontract award. They will be providing Base Client Support Services at Tinker AFB in Oklahoma. The subcontract includes a base year with up to four additional option years and a total value of $11.9 million. Sonal […]
Read more...
On October 10, AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a clinical trial of a drug to treat atopic dermatitis. Based on the current clinical trial results, the efficacy of this drug is much higher than other similar drugs on the market for the treatment of moderate-to-severe atopic dermatitis. Multiple studies also indicate […]
Read more...
Sensor systems developer, FLIR Systems (FLIR), landed a $74.7 million contract with the U.S. military on October 2. They will provide TacFLIR surveillance cameras in support of the U.S. Army EO/IR-Force Protection (FP) program. Sonal detected the event and sent an alert at 8:00 am. The next trade occurred during the pre-market trading hours […]
Read more...
On September 29, the FDA approved Novo-Nordisk’s (NVO) new drug to treat diabetes. Fiasp is fast-acting insulin that controls post-meal spikes in blood sugar. It works faster than existing drugs on the market and is already approved in both Canada and Europe. Sonal caught the news and sent an alert at 11:03 am. The […]
Read more...
On September 29, Zogenix (ZGNX) reported positive results from its phase 3 clinical trial for the drug ZX008. The drug treats a rare form of epilepsy known as Dravet Syndrome. Sonal caught the news at 7:00 am and sent out a level 2 alert. The stock price immediately surged but then faded after the […]
Read more...
On October 2, Sangamo Biosciences (SGMO) and Bioverativ Inc. (BIVV) announced that the FDA accepted their application for an investigational new drug (IND). The drug, ST-400, is a gene-edited cell therapy candidate for people with transfusion-dependent-beta-thalassemia. There are about 100,000 patients being treated worldwide for this disease, which requires frequent blood transfusions. Sonal sent […]
Read more...
On September 26, Akebia Therapeutics (AKBA) reported positive results from a phase 2 clinical trial of the drug Vadadustat. The study results came from Japanese patients with anemia associated with non-dialysis chronic kidney disease and confirmed prior findings. Sonal detected the event and sent out an alert at 7:00 am. The next trade occurred […]
Read more...